| Overview |
| bsm-62616r-apc-cy7-100ul |
| NAT1 Recombinant Monoclonal Antibody, APC-Cy7 Conjugated |
| WB, FCM, IF(ICC) |
| Human |
| Specifications |
| APC-Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NAT1 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 9 |
| P18440 |
| Cytoplasm |
| AAC1; Arylamide acetylase 1; mNAT; N acetyltransferase type 1; nat1. |
| Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz